Literature DB >> 9010682

Serum interleukin-10 in acquired immunodeficiency syndrome lymphoma patients. Seroco-Hemoco Study Group.

L Edelman1, C Deveau, M Raphael, E Monchatre, J Gabarre, A Deville-Chabrol, G Pialoux, D Emilie, I Joab, P Galanaud.   

Abstract

Interleukin-10 (IL-10) has multiple effects on lymphoid development, particularly as a stimulant of activated B-cell proliferation and differentiation. It is thought that IL-10 might play a role in the development of B lymphoid malignancies based on the observation that lymphomatous tissues from HIV+ patients contain numerous cells containing IL-10 mRNA as well as IL-10 protein. The aim of this study using an Elisa test was to analyze IL-10 in the serum of 18 HIV+ patients with non Hodgkin's B lymphoma (NHL) and compared the presence of this cytokine in the serum of 18 HIV+ patients without NHL. In this comparative study we also considered the different parameters such as the mode of contamination, sex, age and number of CD4 cells. 44% of the patients with HIV-related NHL had significant levels of IL-10 (> or = 12 pg/ml) in their serum, in comparison to the patients without NHL who did not show detectable serum IL-10.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010682

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  2 in total

1.  Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10.

Authors:  H D Shin; C Winkler; J C Stephens; J Bream; H Young; J J Goedert; T R O'Brien; D Vlahov; S Buchbinder; J Giorgi; C Rinaldo; S Donfield; A Willoughby; S J O'Brien; M W Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.